Avalo Therapeutics CFO Sullivan Christopher Ryan exercised Options for 10,185 shares at $8.04 per share on 2026-09-10 and sold 10,185 shares at $17.62. For investors, the transactions leave him with 50,085 shares after the exercise, 39,900 after the sale and 105,815 derivative securities.
Key Highlights
- Sullivan Christopher Ryan held 50,085 shares after the option exercise.
- The sale left Avalo Therapeutics’ CFO with 39,900 shares.
- His derivative securities position stood at 105,815 after the exercise, representing about 8.8% of his prior holding.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) CFO Sullivan Christopher Ryan exercised options for 10,185 shares at $8.04 per share on 10 September 2026.
CFO’s Share Transactions on September 10
Following that transaction, Sullivan owned 50,085 Avalo Therapeutics shares, with the exercise representing about 20.3% of his resulting shareholding. A separate transaction code S identified the sale of 10,185 shares at $17.62 per share. After the sale, his shareholding stood at 39,900 shares, and the transaction represented about 20.3% of his prior shareholding.
Derivative Securities Position Reaches 105,815
The option exercise also covered 10,185 derivative securities. Sullivan owned 105,815 derivative securities after that transaction, representing about 8.8% of his prior derivative securities holding.
FAQs
Q: What did Avalo Therapeutics CFO Sullivan Christopher Ryan do?
A: Sullivan Christopher Ryan exercised options for 10,185 Avalo Therapeutics shares at $8.04 per share on 10 September 2026. He also sold 10,185 shares at $17.62 per share.
Q: What was the impact on Sullivan Christopher Ryan’s AVTX shareholding?
A: His Avalo Therapeutics shareholding was 50,085 shares after the option exercise. Following the separate sale, his shareholding stood at 39,900 shares.
Q: How many derivative securities did the Avalo Therapeutics CFO own?
A: Sullivan Christopher Ryan owned 105,815 derivative securities after exercising options. That transaction represented about 8.8% of his prior derivative securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.